½ÃÀ庸°í¼­
»óǰÄÚµå
1812379

¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå

Orthobiologics Market

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Transparency Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 264 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå - Á¶»ç ¹üÀ§

TMRÀÇ Á¶»ç º¸°í¼­ '¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå'Àº 2025-2035³â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥¿¡ ´ëÇÑ °¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®¸¦ ¾ò±â À§ÇØ °ú°Å ¹× ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú ±âȸ¸¦ ¿¬±¸ÇÕ´Ï´Ù. 2025³â ±âÁØ ¿¬µµ, 2035³â ¿¹Ãø¿¬µµ·Î, 2025-2035³â ¼¼°èÀÇ ¿À¸£¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå ¼öÀͰú ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ 2025-2035³â ¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)µµ Á¦°øÇÕ´Ï´Ù.

º» º¸°í¼­´Â ±¤¹üÀ§ÇÑ Á¶»ç¸¦ °ÅÃÄ ÀÛ¼ºµÇ¾ú½À´Ï´Ù. 1Â÷ Á¶»ç¿¡¼­´Â KOL(Key Opinion Leader), ¾÷°è ¸®´õ, ÀÇ°ß Çü¼ºÀÚµé°ú ÀÎÅͺ並 ½Ç½ÃÇß½À´Ï´Ù. 2Â÷ Á¶»ç¿¡¼­´Â ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° ÀÚ·á, ¿¬·Ê º¸°í¼­, º¸µµ ÀÚ·á, °ü·Ã ¹®¼­ µîÀ» ÂüÁ¶ÇÏ¿© ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀåÀ» ÆÄ¾ÇÇß½À´Ï´Ù.

½ÃÀå ÇöȲ
½ÃÀå ¸ÅÃâ(2024³â) 68¾ï ´Þ·¯
½ÃÀå ¸ÅÃâ(2035³â) 122¾ï ´Þ·¯
CAGR 5.5%

º» º¸°í¼­´Â ¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå °æÀï ±¸µµ¸¦ Á¶»çÇß½À´Ï´Ù. ¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÌ È®Àεǰí, ±× °¢ ±â¾÷ÀÌ ´Ù¾çÇÑ ¼Ó¼ºÀ¸·Î ÇÁ·ÎÆÄÀÏ µÇ°í ÀÖ½À´Ï´Ù. ±â¾÷ °³¿ä, À繫 ÇöȲ, ÃÖ±Ù µ¿Çâ, SWOT ºÐ¼®Àº º» º¸°í¼­¿¡¼­ ÇÁ·ÎÆÄÀϸµµÈ ¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå Âü¿© ±â¾÷ ¼Ó¼ºÀÔ´Ï´Ù.

¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • ¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå¿¡¼­ ºñÁî´Ï½º ±âȸ´Â ¹«¾ùÀΰ¡?
  • ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ, ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ, ±âȸ, À§ÇùÀº ¹«¾ùÀΰ¡?
  • ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÏ´Â Áö¿ª ½ÃÀåÀº ¹«¾ùÀΰ¡?
  • 2035³â ¼¼°è¿¡¼­ °¡Àå ³ôÀº ¼öÀÍÀ» ¿Ã¸± °ÍÀ¸·Î ¿¹»óµÇ´Â ºÎ¹®Àº ¹«¾ùÀΰ¡?
  • ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÎ¹®Àº ¹«¾ùÀΰ¡?
  • ¼¼°è ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ´Ù¾çÇÑ ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼ÇÀº ¹«¾ùÀΰ¡?

¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå - Á¶»ç ¸ñÀû ¹× Á¶»ç ±â¹ý

º» Á¶»ç º¸°í¼­´Â ¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå¿¡ ´ëÇØ ¿¬±¸ ¹× ºÐ¼®ÇÑ º¸°í¼­ÀÔ´Ï´Ù. º» º¸°í¼­´Â ¿¬±¸ ¸ñÀû°ú ½ÃÀå ³» ÁÖ¿ä °ø±Þ¾÷ü ¹× À¯Åë¾÷ü, Á¦Ç° ½ÂÀÎ °ü·Ã ±ÔÁ¦ ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ ¼³¸íÀ» Á¦°øÇÕ´Ï´Ù.

µ¶ÇØ ÆíÀǼºÀ» À§ÇØ º¸°í¼­´Â À庰 ±¸¼ºÀ¸·Î Æí¼ºµÇ¾úÀ¸¸ç, °¢ ºÎºÐÀº ¼Ò´ÜÀ§·Î ¼¼ºÐÈ­µÇ¾ú½À´Ï´Ù. º¸°í¼­´Â ÀûÀýÈ÷ ¹èÄ¡µÈ ¹æ´ëÇÑ ±×·¡ÇÁ ¹× Ç¥¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ÁÖ¿ä ºÎ¹®ÀÇ ½ÇÁ¦ ¹× ¿¹»ó °ªÀ» ½Ã°¢ÀûÀ¸·Î Ç¥ÇöÇÑ ³»¿ëÀº µ¶ÀÚ¿¡°Ô ½Ã°¢Àû ¸Å·ÂÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ´Â ¶ÇÇÑ °ú°Å¿Í ¿¹Ãø ±â°£ ¸» ½ÃÁ¡ÀÇ ÁÖ¿ä ºÎ¹® ½ÃÀå Á¡À¯À² ºñ±³¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀåÀ» Á¦Ç°, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº°·Î ºÐ¼®Çß½À´Ï´Ù. °¢ ±âÁØÀÇ ÁÖ¿ä ºÎ¹®À» »ó¼¼ÇÏ°Ô Á¶»çÇϰí 2035³â ¸» ½ÃÁ¡ÀÇ °¢ ºÎ¹®¿¡ ´ëÇÑ ½ÃÀå Á¡À¯À²À» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °¡Ä¡ ÀÖ´Â ÀλçÀÌÆ®´Â ½ÃÀå °ü°èÀÚµéÀÌ Àü ¼¼°èÀÇ ¿À¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå¿¡ ´ëÇÑ ÅõÀÚ¿¡ ´ëÇÑ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ºñÁî´Ï½º ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÀüÁ¦Á¶°Ç°ú Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à : ¼¼°è ½ÃÀå

Á¦4Àå ½ÃÀå °³¿ä

  • ¼Ò°³
  • °³¿ä
  • ½ÃÀå ¿ªÇÐ
  • ¼¼°èÀÇ ¿À¸£¼Ò¹ÙÀÌ¿À·ÎÁ÷½º ½ÃÀå ºÐ¼®°ú ¿¹Ãø(2020-2035³â)

Á¦5Àå ÁÖ¿ä ÀλçÀÌÆ®

  • ÁÖ¿ä ½ÃÀå µ¿Çâ
  • ÁÖ¿ä Áö¿ª ¹× ±¹°¡ÀÇ ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¤Çü¿Ü°ú ¹× ¿Ü»óÇп¡¼­ ÇöÀçÀÇ ¿ªÇÒ
  • Àç»ý ¼ºÇü »ý¹°ÇÐÀû ¿ä¹ý
  • PESTEL ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â »óÀ§ 5°³»ç Àü·«
  • ¿Ü°ú ¼ö¼ú °Ç¼ö

Á¦6Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Á¦Ç°º°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú ¹× ¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : Á¦Ç°º°(2020-2035³â)
    • µ¿Á¾À̽Ä
    • ÀÌÁ¾À̽Ä
    • ÇÕ¼º°ñ À̽Ä
      • ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ®
      • B-Àλê»ïÄ®½·(B-TCP)
      • 2»ó¼º
      • »ýü Ȱ¼º À¯¸®
      • ±âŸ
    • Żȸ°ñ ±âÁú(DBM)
    • °üÀý ³» º¸Ãæ ¿ä¹ý
    • Ç÷¼ÒÆÇ ³óÃà Ç÷Àå(PRP)
    • °ñ¼ö õÀÚ ³óÃà¾×(BMAC)(Áٱ⼼Æ÷ È¥ÇÕ¹°)
    • ±âŸ
  • ½ÃÀå ¸Å·Â ºÐ¼® : Á¦Ç°º°

Á¦7Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ¿ëµµº°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú ¹× ¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : ¿ëµµº°(2020-2035³â)
    • ôÃß°íÁ¤¼ú
    • ¿Ü»óº¹±¸
    • Àç°Ç ¼ö¼ú
    • °ñÀý
    • °ñ°üÀý¿°
    • ÅÎ ¾È¸é ¹× Ä¡°ú¿ëµµ
    • ±âŸ
  • ½ÃÀå ¸Å·Â ºÐ¼® : ¿ëµµº°

Á¦8Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú ¹× ¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : ÃÖÁ¾ »ç¿ëÀÚº°(2020-2035³â)
    • º´¿ø
    • Á¤Çü¿Ü°ú Ŭ¸®´Ð
    • ±âŸ
  • ½ÃÀå ¸Å·Â ºÐ¼® : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦9Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : Áö¿ªº°(2020-2035³â)
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ªº°

Á¦10Àå ºÏ¹Ì ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦11Àå À¯·´ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦13Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦14Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±â¾÷-°æÀï ¸ÅÆ®¸¯½º(±â¾÷ µî±Þº°, ±Ô¸ðº°)
  • ½ÃÀå Á¡À¯À² ºÐ¼® : ±â¾÷º°(2024³â)
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Alphatec Spine Inc.
    • Arthrex
    • Bioventus LLC
    • Exactech Inc.
    • Global Medical Inc.
    • Integra Lifesciences
    • Medtronic
    • MTF Biologics
    • RTI Surgical
    • Sano Orthopedics
    • Sanofi
    • Seikagaku Corporation
HBR 25.09.29

Orthobiologics Market- Scope of Report

TMR's report on the global Orthobiologics Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Orthobiologics Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Orthobiologics Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Orthobiologics Market .

Market Snapshot
Market Value in 2024US$ 6.8 Bn
Market Value in 2035US$ 12.2 Bn
CAGR5.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Orthobiologics Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Orthobiologics Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Orthobiologics Market .

The report delves into the competitive landscape of the global Orthobiologics Market . Key players operating in the global Orthobiologics Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Orthobiologics Marketprofiled in this report.

Key Questions Answered in Global Orthobiologics MarketReport:

  • What are the opportunities in the global Orthobiologics Market ?
  • What are the major drivers, restraints, opportunities, and threats in the Market ?
  • Which regional Market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the Market positions of different companies operating in the global Market ?

Orthobiologics Market- Research Objectives and Research Approach

The comprehensive report on the global Orthobiologics Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Orthobiologics Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Orthobiologics Market .

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Orthobiologics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Orthobiologics Market Analysis and Forecast, 2020 to 2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Key Market Trends
  • 5.2. Regulatory Scenario across Key Regions/Countries
  • 5.3. Current role in Orthopedic Surgery and Traumatology
  • 5.4. Regenerative Orthobiologic Therapy
  • 5.5. PESTEL Analysis
  • 5.6. PORTER's Analysis
  • 5.7. Strategies of Top Five Players Operating in the Market
  • 5.8. Number of Surgical Procedures

6. Global Orthobiologics Market Analysis and Forecast, by Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product, 2020 to 2035
    • 6.3.1. Allografts
    • 6.3.2. Xenografts
    • 6.3.3. Synthetic Bone Grafts
      • 6.3.3.1. Hydroxyapatite
      • 6.3.3.2. B-tricalcium phosphate (B-TCP)
      • 6.3.3.3. BiPhasic
      • 6.3.3.4. Bioactive glass
      • 6.3.3.5. Others
    • 6.3.4. Demineralized Bone Matrix (DBM)
    • 6.3.5. Viscosupplementation
    • 6.3.6. Platelet-rich plasma (PRP)
    • 6.3.7. Bone marrow aspirate concentrate (BMAC) (Mixture of Stem Cells)
    • 6.3.8. Others
  • 6.4. Market Attractiveness Analysis, by Product

7. Global Orthobiologics Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Application, 2020 to 2035
    • 7.3.1. Spinal Fusion
    • 7.3.2. Trauma Repair
    • 7.3.3. Reconstructive Surgeries
    • 7.3.4. Fractures
    • 7.3.5. Osteoarthritis
    • 7.3.6. Maxillofacial and Dental Applications
    • 7.3.7. Others
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Orthobiologics Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020 to 2035
    • 8.3.1. Hospitals
    • 8.3.2. Orthopedic Clinics
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Orthobiologics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020 to 2035
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Orthobiologics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product, 2020 to 2035
    • 10.2.1. Allografts
    • 10.2.2. Xenografts
    • 10.2.3. Synthetic Bone Grafts
      • 10.2.3.1. Hydroxyapatite
      • 10.2.3.2. B-tricalcium phosphate (B-TCP)
      • 10.2.3.3. BiPhasic
      • 10.2.3.4. Bioactive glass
      • 10.2.3.5. Others
    • 10.2.4. Demineralized Bone Matrix (DBM)
    • 10.2.5. Viscosupplementation
    • 10.2.6. Platelet-rich plasma (PRP)
    • 10.2.7. Bone marrow aspirate concentrate (BMAC) (Mixture of Stem Cells)
    • 10.2.8. Others
  • 10.3. Market Value Forecast, by Application, 2020 to 2035
    • 10.3.1. Spinal Fusion
    • 10.3.2. Trauma Repair
    • 10.3.3. Reconstructive Surgeries
    • 10.3.4. Fractures
    • 10.3.5. Osteoarthritis
    • 10.3.6. Maxillofacial and Dental Applications
    • 10.3.7. Others
  • 10.4. Market Value Forecast, by End-user, 2020 to 2035
    • 10.4.1. Hospitals
    • 10.4.2. Orthopedic Clinics
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Country, 2020 to 2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Product
    • 10.6.2. By Application
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Orthobiologics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Product, 2020 to 2035
    • 11.2.1. Allografts
    • 11.2.2. Xenografts
    • 11.2.3. Synthetic Bone Grafts
      • 11.2.3.1. Hydroxyapatite
      • 11.2.3.2. B-tricalcium phosphate (B-TCP)
      • 11.2.3.3. BiPhasic
      • 11.2.3.4. Bioactive glass
      • 11.2.3.5. Others
    • 11.2.4. Demineralized Bone Matrix (DBM)
    • 11.2.5. Viscosupplementation
    • 11.2.6. Platelet-rich plasma (PRP)
    • 11.2.7. Bone marrow aspirate concentrate (BMAC) (Mixture of Stem Cells)
    • 11.2.8. Others
  • 11.3. Market Value Forecast, by Application, 2020 to 2035
    • 11.3.1. Spinal Fusion
    • 11.3.2. Trauma Repair
    • 11.3.3. Reconstructive Surgeries
    • 11.3.4. Fractures
    • 11.3.5. Osteoarthritis
    • 11.3.6. Maxillofacial and Dental Applications
    • 11.3.7. Others
  • 11.4. Market Value Forecast, by End-user, 2020 to 2035
    • 11.4.1. Hospitals
    • 11.4.2. Orthopedic Clinics
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 11.5.1. Germany
    • 11.5.2. UK
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Switzerland
    • 11.5.7. The Netherlands
    • 11.5.8. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Product
    • 11.6.2. By Application
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Orthobiologics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product, 2020 to 2035
    • 12.2.1. Allografts
    • 12.2.2. Xenografts
    • 12.2.3. Synthetic Bone Grafts
      • 12.2.3.1. Hydroxyapatite
      • 12.2.3.2. B-tricalcium phosphate (B-TCP)
      • 12.2.3.3. BiPhasic
      • 12.2.3.4. Bioactive glass
      • 12.2.3.5. Others
    • 12.2.4. Demineralized Bone Matrix (DBM)
    • 12.2.5. Viscosupplementation
    • 12.2.6. Platelet-rich plasma (PRP)
    • 12.2.7. Bone marrow aspirate concentrate (BMAC) (Mixture of Stem Cells)
    • 12.2.8. Others
  • 12.3. Market Value Forecast, by Application, 2020 to 2035
    • 12.3.1. Spinal Fusion
    • 12.3.2. Trauma Repair
    • 12.3.3. Reconstructive Surgeries
    • 12.3.4. Fractures
    • 12.3.5. Osteoarthritis
    • 12.3.6. Maxillofacial and Dental Applications
    • 12.3.7. Others
  • 12.4. Market Value Forecast, by End-user, 2020 to 2035
    • 12.4.1. Hospitals
    • 12.4.2. Orthopedic Clinics
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 12.5.1. China
    • 12.5.2. India
    • 12.5.3. Japan
    • 12.5.4. South Korea
    • 12.5.5. Australia & New Zealand
    • 12.5.6. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Product
    • 12.6.2. By Application
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Orthobiologics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product, 2020 to 2035
    • 13.2.1. Allografts
    • 13.2.2. Xenografts
    • 13.2.3. Synthetic Bone Grafts
      • 13.2.3.1. Hydroxyapatite
      • 13.2.3.2. B-tricalcium phosphate (B-TCP)
      • 13.2.3.3. BiPhasic
      • 13.2.3.4. Bioactive glass
      • 13.2.3.5. Others
    • 13.2.4. Demineralized Bone Matrix (DBM)
    • 13.2.5. Viscosupplementation
    • 13.2.6. Platelet-rich plasma (PRP)
    • 13.2.7. Bone marrow aspirate concentrate (BMAC) (Mixture of Stem Cells)
    • 13.2.8. Others
  • 13.3. Market Value Forecast, by Application, 2020 to 2035
    • 13.3.1. Spinal Fusion
    • 13.3.2. Trauma Repair
    • 13.3.3. Reconstructive Surgeries
    • 13.3.4. Fractures
    • 13.3.5. Osteoarthritis
    • 13.3.6. Maxillofacial and Dental Applications
    • 13.3.7. Others
  • 13.4. Market Value Forecast, by End-user, 2020 to 2035
    • 13.4.1. Hospitals
    • 13.4.2. Orthopedic Clinics
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Argentina
    • 13.5.4. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Product
    • 13.6.2. By Application
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Orthobiologics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product, 2020 to 2035
    • 14.2.1. Allografts
    • 14.2.2. Xenografts
    • 14.2.3. Synthetic Bone Grafts
      • 14.2.3.1. Hydroxyapatite
      • 14.2.3.2. B-tricalcium phosphate (B-TCP)
      • 14.2.3.3. BiPhasic
      • 14.2.3.4. Bioactive glass
      • 14.2.3.5. Others
    • 14.2.4. Demineralized Bone Matrix (DBM)
    • 14.2.5. Viscosupplementation
    • 14.2.6. Platelet-rich plasma (PRP)
    • 14.2.7. Bone marrow aspirate concentrate (BMAC) (Mixture of Stem Cells)
    • 14.2.8. Others
  • 14.3. Market Value Forecast, by Application, 2020 to 2035
    • 14.3.1. Spinal Fusion
    • 14.3.2. Trauma Repair
    • 14.3.3. Reconstructive Surgeries
    • 14.3.4. Fractures
    • 14.3.5. Osteoarthritis
    • 14.3.6. Maxillofacial and Dental Applications
    • 14.3.7. Others
  • 14.4. Market Value Forecast, by End-user, 2020 to 2035
    • 14.4.1. Hospitals
    • 14.4.2. Orthopedic Clinics
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Product
    • 14.6.2. By Application
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. Alphatec Spine Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Arthrex
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Bioventus LLC
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Exactech Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Global Medical Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Integra Lifesciences
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Medtronic
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. MTF Biologics
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. RTI Surgical
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Sano Orthopedics
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Product Portfolio
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments
    • 15.3.11. Sanofi
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments
    • 15.3.12. Seikagaku Corporation
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Product Portfolio
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Developments
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦